Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation.

Autor:	Satti DI; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Karius A; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Chan JSK; Cardiovascular Analytics Group, Hong Kong-China-UK Collaboration, Hong Kong., Isakadze N; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Yadav R; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Garg K; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Aronis KN; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Marine JE; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Berger R; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Calkins H; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Spragg D; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: dspragg1@jhmi.edu.
Jazyk:	angličtina
Zdroj:	JACC. Clinical electrophysiology [JACC Clin Electrophysiol] 2024 Aug; Vol. 10 (8), pp. 1848-1855. Date of Electronic Publication: 2024 May 22.
DOI:	10.1016/j.jacep.2024.03.031
Abstrakt:	Background: Relationship between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use prior to atrial fibrillation (AF) ablation and subsequent AF recurrence is not well-understood. Objectives: This study investigated the effects of GLP-1 RA use within 1 year before ablation and its association with AF recurrence and associated outcomes. Methods: The TriNetX research database was used to identify patients aged ≥18 years undergoing AF ablation (2014-2023). Patients were categorized into 2 groups, and propensity score matching (1:1) between preablation GLP-1 RA users and nonusers was performed based on demographics, comorbidities, body mass index, laboratory tests, AF subtype, and medications. Primary outcome was composite of cardioversion, new antiarrhythmic drug therapy, or repeat AF ablation after a 3-month blanking period following the index ablation. Additional outcomes included ischemic stroke, all-cause hospitalization, and mortality during 12-month follow-up period. Results: After 1:1 propensity score matching, the study cohort comprised 1,625 GLP-1 RA users and 1,625 matched GLP-1 RA nonusers. Preablation GLP-1 RA therapy was not associated with a lower risk of cardioversion, new AAD therapy, and repeat AF ablation after the index procedure (HR: 1.04 [95% CI: 0.92-1.19]; log-rank P = 0.51). Furthermore, the risk of ischemic stroke, all-cause hospitalization, and mortality during the 12-month follow-up period did not differ between the 2 groups. Conclusions: These findings suggest that preprocedural use of GLP-1 RAs is not associated with a reduced risk of AF recurrence or associated adverse outcomes following ablation, and underscore the need for future research to determine whether these agents improve outcome in AF patients. Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu